Chapter 10. Long-Term Anticoagulation in Venous Thromboembolism

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. Clive Kearon MB, MRCPI, FRCPC, PhD

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch10

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Kearon, C. (2008) Long-Term Anticoagulation in Venous Thromboembolism, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch10

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. McMaster University, Hamilton, Ontario, Canada

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857



  • Long-term treatment of venous thromboembolism (VTE);
  • vitamin K antagonist therapy management;
  • optimal intensity of Vitamin K antagonist therapy;
  • anticoagulant therapy duration;
  • patient-related risk factors for recurrent VTE after anticoagulant therapy stoppage;
  • Residual deep vein thrombosis;
  • bleeding during long-term anticoagulant therapy;
  • balancing reduction of VTE with bleeding during long-term therapy;
  • patient preferences and burden of anticoagulation


This chapter contains sections titled:

  • Management of vitamin K antagonist therapy

  • Duration of Anticoagulant Therapy

  • Comparisons of different durations of anticoagulation therapy for venous thromboembolism

  • Bleeding during long-term anticoagulant therapy

  • Balancing reduction of VTE with increase of bleeding during long-term therapy

  • Patient preferences and the burden of anticoagulation

  • Alternatives to vitamin K antagonists

  • Recommended duration of anticoagulation in individual patients

  • References